As part of its review of the Orphan and Paediatric Regulations announced in 2020, the European Commission (EC) has launched a public consultation for stakeholders such as patient organisations, healthcare professionals and providers, researchers, academics and representatives of the pharmaceutical industry, as well as members of the general public.
Interested parties are invited to share their views and experiences on the main obstacles they are facing concerning treatments for rare diseases and children, on possible ways to overcome these obstacles and on how to make the current legislation future-proof.
The public consultation is currently accepting inputs as a questionnaire and will close on July 30, 2021.
More information here: https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12767-Medicines-for-children-&-rare-diseases-updated-rules/public-consultation_en
